New bladder cancer combo aims to boost immune attack

NCT ID NCT06963346

Summary

This early-stage study is testing whether adding a drug called romidepsin directly into the bladder can help another drug (durvalumab) work better against muscle-invasive bladder cancer. It is for patients who are not eligible for standard cisplatin chemotherapy. The main goal is to find a safe dose and see if the treatment helps shrink the tumor before surgery.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

Conditions

Explore the condition pages connected to this study.